Duke University Medical Center
Durham, North Carolina, 27705, United States
NCT Number: NCT05431127
Study Objectives: 1) assess the safety and feasibility of high-dose inspiratory muscle training (IMT) delivered remotely in Late-onset Pompe Disease (LOPD) and 2) determine its effects on respiratory and patient-reported outcomes.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Durham, North Carolina, 27705, United States
This study aims to develop treatments that enhance respiratory strength and function to provide meaningful clinical improvements for people with LOPD. Identification of a cost-effective adjunctive intervention to address respiratory weakness remains critical to reduce disease burden, ease activity limitations and participation restrictions, and improve health-related quality of life. The proposed study will provide a high-dose inspiratory muscle training (IMT) stimulus to enhance treatment efficacy and efficiency. Our hypothesis is that high-dose IMT is necessary to produce meaningful changes in respiratory muscle strength and other outcomes in participants with LOPD.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Inspiratory Muscle Training using a device used to measure and increase respiratory strength and performance through resisted breathing exercises.
Time frame: Baseline, week 15, week 30
Change pre-test to post test, measured in cm H20
Time frame: Baseline, week 15, week 30
Change pre-test to post test, measured in cm H20
Time frame: Baseline, week 15, week 30
Change pre-test to post test, measured in pressure-time units (PTUs)
Time frame: Baseline, week 15, week 30
Change pre-test to post test, measured by duration in seconds
Time frame: Baseline, week 15, week 30
Change pre-test to post test, a proprietary measure which quantifies propensity to inspiratory muscle fatigue based upon the relationship between inspiratory capacity and demand using the following equation: (IPC [in Watts] x MID) / (Power500 x T500), where Power500 = power expended to inspire a mass of 500 mL air and T500 = time when mass of inspired air=500 mL at sea level
Time frame: Baseline, week 15, week 30
Change pre-test to post-test, measured in liters using a portable hand-held spirometer
Time frame: Baseline, week 15, week 30
change pre-test to post-test, measured in liters per second using a portable hand-held spirometer
Time frame: Baseline, week 15, week 30
change pre-test to post-test, measured in liters per second using portable hand-held spirometer
Time frame: Baseline, week 15, week 30
change pre-test to post-test, measured in seconds
Time frame: Baseline, week 15, week 30
Change pre-test to post-test, measured in liters per second
Time frame: Baseline, week 15, week 30
Change pre-test to post-test, measured in seconds
Time frame: Baseline, week 15, week 30
Change pre-test to post-test, measured in liters per second
Time frame: Baseline, week 15, week 30
Change pre-test to post-test, measured by EPF/EPRT
Time frame: Baseline, week 15, week 30
Change pre-test to post-test, measured by Fatigue Severity Scale (FSS) survey completion, using a 7 point ordinal scale where a rating of 1 indicates strong disagreement and a rating of 7 indicates strong agreement.
Time frame: Baseline, week 15, week 30
Change pre-test to post-test, measured by Modified Fatigue Impact Scale (MFIS) survey completion using a score of 0 (never affected) to 4 (almost always affected). The total score ranges from 0 to a maximum of 84. Higher scores indicate greater impact of fatigue on quality of life.
Time frame: Baseline, week 15, week 30
Change pre-test to post-test, measured by Epworth Sleepiness Scale (ESS) survey completion using a 0 to 3 ordinal scale in which 0=no chance of dozing, 1=slight chance of dozing, 2= moderate chance of dozing, and 3=high chance of dozing. Scores are summed to obtain total ESS score where a score >10 reflects excessive daytime sleepiness.
Time frame: Baseline, week 15, week 30
Change pre-test to post-test, measured by Pittsburgh Sleep Quality Index (PSQI) survey completion. The PSQI is a 9-question, 19-item instrument. Items 1 to 4 are open-ended questions (customary bedtime, length of time to fall asleep). Items 5 to 8 (including the 10 questions comprising item 5) are sleep symptoms which are rated as to their frequency using an ordinal scale: 0=not occurring in the last month, 1=less than once a week, 2=once or twice a week, and 3=three or more times a week. Item 9 is a rating of overall sleep quality over the past month using a 0 to 3 ordinal scale: 0=very good; 1=fairly good; 2= fairly bad; and 3=very bad. Scores from the 19-items are combined according to standard scoring criteria to obtain a Global PSQI score. Scores >5 indicate reduced sleep quality.
Time frame: Baseline, week 15, week 30
Change pre-test to post-test, measured by Respiratory Symptoms Questionnaire (RSQ) completion using a 0-3 scale where a higher score indicates worse symptoms.
Time frame: Baseline, week 15, week 30
Change pre-test to post-test, measured by Rotterdam Handicap Scale (RHS) survey completion using a ranging scale of 1 - 4 where 1 = unable to fulfil the task or activity and 4 = complete fulfillment of the task or activity. Scores are summed and range from 9-36.
Time frame: Baseline, week 15, week 30
Change pre-test to post-test, measured by Short Form 36 (SF-36) survey completion where physical and mental component summary scales (PCS and MCS) are calculated from the subscales and transformed to a normalized T-score with a mean of 50 and a standard deviation of 10. Higher scores represent better health-related quality of life.
Time frame: Baseline, week 15, week 30
Change pre-test to post-test, measured by Communicative Participation Item Bank-Short From (CPIB-10) survey completion using a 4-point scale (not at all=3, a little=2, quite a bit=1, very much=0). Item scores are added to obtain the summary score which ranges from 0-30. This can be transformed into a standard T score (mean=50, SD=10). Higher scores represent less interference in communication participation.
Time frame: Baseline, week 15, week 30
Change pre-test to post-test, measured by Voice Handicap Index (VHI-10) survey completion using a 5-point scale (0=never, 1=almost never, 2=sometimes, 3=almost always, 4=always). Item responses are added to obtain a total score (values >11 abnormal) with higher scores indicating greater perception of voice-related handicap.
Time frame: Baseline, week 15, week 30
Change pre-test to post-test, measured by Eating Assessment Tool (EAT-10) survey completion using a 5-point scale (0=no problem, 4=severe problem). Item responses are added to obtain a total score (values >3 abnormal) with higher scores indicating greater severity of swallowing symptoms.
Duke University
Other
High-dose Inspiratory Muscle Training (IMT) in Late-onset Pompe Disease (LOPD)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07685314
Brain Diseases, Brain Diseases, Metabolic
Seville, Spain
View Trial DetailsNCT07354724
Brain Diseases, Brain Diseases, Metabolic
Irvine, California, United States
View Trial DetailsNCT07494058
Lysosomal Disease
Mexico City, Mexico
View Trial Details